Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Serum and Mucosal RSV Antibodies Following Clesrovimab (Enflonsia™, Merck) Administration in Infants During Their First Respiratory Season or [The EMBRACE Study: Enflonsia™ Monoclonal in Babies - RSV Antibody Concentration Evaluation]

NCT07824167 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT07824167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Serum and Mucosal RSV Antibodies Following Clesrovimab (Enflonsia™, Merck) Administration in Infants During Their First Respiratory Season or [The EMBRACE Study: Enflonsia™ Monoclonal in Babies - RSV Antibody Concentration Evaluation]
Lead sponsor
Emory University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rsv infection